STOP 301: A Phase 3, open-label study of safety,tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD®) of dihydroergotamine mesylate,over 24/52 weeks in acute treatment of migraine attacks in adult patients 期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

STOP 301: A Phase 3, open-label study of safety,tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD®) of dihydroergotamine mesylate,over 24/52 weeks in acute treatment of migraine attacks in adult patients

摘要：